How essential are in‐person clinic visits during maintenance treatment of children with acute lymphoblastic leukemia?-Reference-Cited by-同舟云学术

How essential are in‐person clinic visits during maintenance treatment of children with acute lymphoblastic leukemia?

Published:2022-04-11 Issue:7 Volume:69 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Rabinowicz Ron¹^ORCID,Maguire Bryan²,Hitzler Johann¹³⁴^ORCID,Punnett Angela¹³^ORCID

Affiliation:

1. Division of Hematology/Oncology The Hospital for Sick Children Toronto Ontario Canada

2. Biostatistics, Design and Analysis, Research Institute The Hospital for Sick Children Toronto Ontario Canada

3. Department of Pediatrics University of Toronto Toronto Ontario Canada

4. Developmental and Stem Cell Biology The Hospital for Sick Children Research Institute Toronto Ontario Canada

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29713

Reference24 articles.

1. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331

2. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia

3. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group

4. AALL1731 ‐ a phase 3 trial investigating blinatumomab (NSC# 765986) in combination with chemotherapy in patients with newly diagnosed standard risk or Down syndrome B‐lymphoblastic leukemia (B‐ALL) and the treatment of patients with localized B‐lymphoblastic lymphoma (B‐LLy). NIH; 2019.http://clinicaltrials.gov/ct2/show/NCT03914625.Accessed on September 16 2021

5. AALL1732 ‐ a phase 3 randomized trial of inotuzumab ozogamicin (NSC#: 772518) for newly diagnosed high‐risk B‐ALL; risk‐adapted post‐induction therapy for high‐risk B‐ALL mixed phenotype acute leukemia and disseminated B‐LLy. NIH; 2019.http://clinicaltrials.gov/ct2/show/NCT03959085.Accessed on September 16 2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hybrid Email and Outpatient Clinics to Optimize Maintenance Therapy in Acute Lymphoblastic Leukemia;Journal of Pediatric Hematology/Oncology;2023-12-12

2. Can virtual care reduce treatment burden in pediatric leukemia? A retrospective cost analysis;Pediatric Blood & Cancer;2023-06-19

3. The new reality is virtual;Pediatric Blood & Cancer;2022-05-13